Literature DB >> 31629966

Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook.

Fakhara Sabir1, Ruba Ismail1, Ildiko Csoka2.   

Abstract

Glioblastoma multiforme (GBM) is one of the most devastating and deadly types of tumor. Among all the present treatment strategies, the utmost prerequisite is prolonged intervention at the malignant site. The blood-brain barrier (BBB) is the bottleneck in the delivery of anti-GBM drugs and invasive treatment comes with many pitfalls. This review will discuss the potential of embedding antitumor drugs into nanocarriers for intranasal delivery. Additionally, it emphasizes the significance of applying quality by design (QbD) methodology from the early development stages to ensure the high quality, safety and efficacy of the developed carrier system.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31629966     DOI： 10.1016/j.drudis.2019.10.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  9 in total

Review 1.  Strategies for delivering therapeutics across the blood-brain barrier.

Authors:  Georg C Terstappen; Axel H Meyer; Robert D Bell; Wandong Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-03-01       Impact factor: 84.694

Review 2.  Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review.

Authors:  Fatemeh Moradi; Nasrin Dashti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-04       Impact factor: 3.000

3.  Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.

Authors:  Rita Ambrus; Péter Gieszinger; Róbert Gáspár; Anita Sztojkov-Ivanov; Eszter Ducza; Árpád Márki; Tamás Janáky; Ferenc Tömösi; Gábor Kecskeméti; Piroska Szabó-Révész; Csilla Bartos
Journal:  Molecules       Date:  2020-02-27       Impact factor: 4.411

Review 4.  Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches.

Authors:  Ksenia Mitusova; Oleksii O Peltek; Timofey E Karpov; Albert R Muslimov; Mikhail V Zyuzin; Alexander S Timin
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

5.  Nose to brain delivery of melatonin lipidic nanocapsules as a promising post-ischemic neuroprotective therapeutic modality.

Authors:  Eman A Bseiso; Sarah A AbdEl-Aal; Maha Nasr; Omaima A Sammour; Nabaweya A Abd El Gawad
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy.

Authors:  Rong Sun; Mingzhu Liu; Jianping Lu; Binbin Chu; Yunmin Yang; Bin Song; Houyu Wang; Yao He
Journal:  Nat Commun       Date:  2022-09-01       Impact factor: 17.694

Review 7.  New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery.

Authors:  Yaosheng Li; Honghui Wu; Xinchi Jiang; Yunfei Dong; Juanjuan Zheng; Jianqing Gao
Journal:  Acta Pharm Sin B       Date:  2022-04-07       Impact factor: 14.903

Review 8.  Pharmacokinetics and Pharmacodynamics of Intranasal Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Nose-to-Brain Delivery.

Authors:  Thi-Thao-Linh Nguyen; Han-Joo Maeng
Journal:  Pharmaceutics       Date:  2022-03-05       Impact factor: 6.321

Review 9.  Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art.

Authors:  Leonardo Delello Di Filippo; Jonatas Lobato Duarte; Marcela Tavares Luiz; Jennifer Thayanne Cavalcante de Araújo; Marlus Chorilli
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.